CTOs on the Move

Y-mAbs Therapeutics

www.ymabs.com

 
YmAbs has a powerful set of capabilities for the development of biologics. Our product development team includes some of the most talented and experienced professionals in the antibody industry.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.ymabs.com
  • 750 Third Avenue 9th Floor
    New York, NY USA 10017
  • Phone: 212.847.9841

Executives

Name Title Contact Details

Funding

Y-mAbs Therapeutics raised $30M on 11/29/2017
Y-mAbs Therapeutics raised $115M on 02/17/2021

Similar Companies

Be Biopharma

Be Biopharma is a leader in developing B cells as medicines, treating disease with the human body`s native protein factories. We precisely engineer B cells to harness their intrinsic drug-like properties – remarkable protein production, selective tissue targeting, and fine control of their cellular environment – to forge a new category of cell therapy. These medicines are designed to be durable, allogeneic, re-dosable, and administered without toxic conditioning, creating new avenues to halt or reverse severe diseases like cancer, autoimmune conditions, and enzyme deficiency. Founded by Longwood Fund and B cell engineering pioneers David Rawlings, M.D., and Richard James, Ph.D., Be Biopharma is re-imagining medicine based on the power of B cell therapy. Be Bio was founded in October 2020 by Longwood Fund with a $52 million Series A investment led by Atlas Ventures and RA Capital, joined by Alta Partners and Takeda Ventures.

Abengoa

Abengoa applies innovative technology solutions for sustainability in the energy and environment sectors, generating electricity from renewable resources, converting biomass into biofuels and producing drinking water from sea water. Abengoa’s business is structured around three activities.

Celsis Inc

Celsis Inc is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Federation Bio

Federation Bio is a biotechnology company pioneering a novel approach to create potent, durable and safe cell therapies. The company`s first-in-class platform combines the power of genetic engineering and synthetic consortium design to control systemic immune responses and broad metabolic functions. Federation Bio`s pipeline addresses a range of serious illnesses from metabolic disorders to metastatic cancer. The company`s lead program is in enteric hyperoxaluria, a serious renal condition that affects more than 250,000 Americans and for which there are currently no approved therapies.

Specialty Flooring Systems Inc

Specialty Flooring Systems Inc is a South Amboy, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.